$ARTH
Arch Therapeutics, Inc.

2018 Q2 Form 10-Q Financial Statement

#000114420418041594 Filed on August 02, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2017 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $990.0K $1.310M
YoY Change -24.43% 1.55%
% of Gross Profit
Research & Development $634.0K $534.6K
YoY Change 18.59% 21.89%
% of Gross Profit
Depreciation & Amortization $1.706K $358.00
YoY Change 376.54%
% of Gross Profit
Operating Expenses $1.620M $1.841M
YoY Change -12.0% 6.26%
Operating Profit -$1.620M -$1.841M
YoY Change -12.0% 6.26%
Interest Expense $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.210M -$1.780M
YoY Change 24.16% 0.56%
Income Tax
% Of Pretax Income
Net Earnings -$2.213M -$1.776M
YoY Change 24.6% 0.56%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$14.68K -$12.11K
COMMON SHARES
Basic Shares Outstanding 150.6M shares 150.8M shares
Diluted Shares Outstanding 150.6M shares

Balance Sheet

Concept 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.490M $6.170M
YoY Change 5.19% 7.3%
Cash & Equivalents $6.489M $6.169M
Short-Term Investments
Other Short-Term Assets $90.00K $150.0K
YoY Change -40.0% -6.25%
Inventory
Prepaid Expenses $87.73K
Receivables
Other Receivables
Total Short-Term Assets $6.577M $6.320M
YoY Change 4.06% 7.12%
LONG-TERM ASSETS
Property, Plant & Equipment $19.12K $3.458K
YoY Change 452.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.500K
YoY Change
Total Long-Term Assets $22.62K $3.458K
YoY Change 554.16%
TOTAL ASSETS
Total Short-Term Assets $6.577M $6.320M
Total Long-Term Assets $22.62K $3.458K
Total Assets $6.599M $6.320M
YoY Change 4.42% 7.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $183.2K $210.0K
YoY Change -12.78% -57.14%
Accrued Expenses $180.0K $160.0K
YoY Change 12.5% -15.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $358.8K $370.3K
YoY Change -3.11% -45.54%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $3.990M $2.570M
YoY Change 55.25% 756.67%
Total Long-Term Liabilities $3.990M $2.570M
YoY Change 55.25% 100.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $358.8K $370.3K
Total Long-Term Liabilities $3.990M $2.570M
Total Liabilities $4.349M $2.940M
YoY Change 47.92% 50.0%
SHAREHOLDERS EQUITY
Retained Earnings -$32.88M
YoY Change
Common Stock $33.00M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.251M $3.380M
YoY Change
Total Liabilities & Shareholders Equity $6.599M $6.320M
YoY Change 4.42% 7.12%

Cashflow Statement

Concept 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$2.213M -$1.776M
YoY Change 24.6% 0.56%
Depreciation, Depletion And Amortization $1.706K $358.00
YoY Change 376.54%
Cash From Operating Activities -$1.420M -$980.0K
YoY Change 44.9% -26.32%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.540M -90.00K
YoY Change -5144.44% -101.66%
NET CHANGE
Cash From Operating Activities -1.420M -980.0K
Cash From Investing Activities -10.00K 0.000
Cash From Financing Activities 4.540M -90.00K
Net Change In Cash 3.110M -1.070M
YoY Change -390.65% -126.23%
FREE CASH FLOW
Cash From Operating Activities -$1.420M -$980.0K
Capital Expenditures -$10.00K $0.00
Free Cash Flow -$1.410M -$980.0K
YoY Change 43.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
154052013 shares
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
153692857 shares
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
986113 USD
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1306435 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2987012 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3827283 USD
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
634021 USD
CY2018Q2 us-gaap Revenues
Revenues
0 USD
CY2017Q2 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
us-gaap Net Income Loss
NetIncomeLoss
-3378825 USD
us-gaap Net Income Loss
NetIncomeLoss
-5046674 USD
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Use of Estimates</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q2 us-gaap Cash
Cash
6489101 USD
CY2017Q3 us-gaap Cash
Cash
5994052 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
534631 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2229340 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1593838 USD
us-gaap Depreciation
Depreciation
3561 USD
us-gaap Depreciation
Depreciation
835 USD
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
154052013 shares
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
153692857 shares
CY2018Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
87725 USD
CY2017Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
85343 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Concentration of Credit Risk</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q2 us-gaap Assets Current
AssetsCurrent
6576826 USD
CY2017Q3 us-gaap Assets Current
AssetsCurrent
6079395 USD
CY2018Q2 us-gaap Depreciation
Depreciation
1706 USD
CY2017Q2 us-gaap Depreciation
Depreciation
358 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1282052 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1578663 USD
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
1620134 USD
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
1841066 USD
us-gaap Operating Expenses
OperatingExpenses
5216352 USD
us-gaap Operating Expenses
OperatingExpenses
5421121 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1620134 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1841066 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-5216352 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-5421121 USD
arth Noncash Interest Expense On Notes Payable
NoncashInterestExpenseOnNotesPayable
0 USD
arth Noncash Interest Expense On Notes Payable
NoncashInterestExpenseOnNotesPayable
22118 USD
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19121 USD
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7188 USD
us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
0 USD
us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-162000 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-1837527 USD
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-426832 USD
CY2017Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
65326 USD
CY2018Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-592506 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
1837527 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
426832 USD
CY2018Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3500 USD
CY2017Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3500 USD
CY2018Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
22621 USD
CY2017Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
10688 USD
CY2018Q2 us-gaap Interest Expense
InterestExpense
0 USD
CY2017Q2 us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
52385 USD
dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q2 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-592506 USD
CY2017Q2 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
65326 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1837527 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
374447 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2382 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
43508 USD
CY2018Q2 us-gaap Assets
Assets
6599447 USD
CY2017Q3 us-gaap Assets
Assets
6090083 USD
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14634210 shares
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
358807 USD
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
433531 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1040000 shares
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-2212640 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-1775740 USD
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
Arch Therapeutics, Inc.
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-81722 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-168762 USD
CY2018Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
28105 USD
CY2017Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12611 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
225000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1078332 shares
CY2018Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets
8984 USD
CY2017Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets
5423 USD
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
183154 USD
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
264876 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-73002 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-135303 USD
dei Entity Central Index Key
EntityCentralIndexKey
0001537561
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-331000 USD
CY2018Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
175653 USD
CY2017Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
168655 USD
us-gaap Derivatives Reporting Of Derivative Activity
DerivativesReportingOfDerivativeActivity
<div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Derivative Liabilities</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"><div style="text-decoration: none; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px;">The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815,<div style="text-decoration: none; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-style:italic;display:inline;">Derivatives and Hedging</div>. Warrants classified as equity are recorded at fair value as of the date of issuance on the Company’s consolidated balance sheets and no further adjustments to their valuation are made. Warrants classified as derivative liabilities and other derivative financial instruments that require separate accounting as liabilities are recorded on the Company’s consolidated balance sheets at their fair value on the date of issuance and will be revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of these liabilities using option pricing models and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life, yield, and risk-free interest rate.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14370878 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
12334062 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4087845 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4388463 USD
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Accelerated Filer
dei Trading Symbol
TradingSymbol
ARTH
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
147019042 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
150331682 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
140924128 shares
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
150550189 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
14370878 shares
CY2018Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
3989960 USD
CY2017Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
3430033 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15494 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4293 USD
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
164297013 shares
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15494 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4293 USD
CY2018Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3989960 USD
CY2017Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3430033 USD
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.39
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.48
CY2018Q2 us-gaap Liabilities
Liabilities
4348767 USD
CY2017Q3 us-gaap Liabilities
Liabilities
3863564 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
63388 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
537659 USD
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.37
CY2018Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
0 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
0 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
52000 USD
CY2017Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
0 USD
CY2018Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
0 USD
CY2017Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
0 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.41
arth Proceeds From Subscribed But Unissued Common Stock And Warrants
ProceedsFromSubscribedButUnissuedCommonStockAndWarrants
4535000 USD
arth Proceeds From Subscribed But Unissued Common Stock And Warrants
ProceedsFromSubscribedButUnissuedCommonStockAndWarrants
0 USD
arth Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0 USD
arth Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
5987122 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.39
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
150535 USD
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
149943 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.37
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1000000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
495049 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1132025 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.39
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5994052 USD
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5036476 USD
CY2017Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
2996110 USD
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
433923 USD
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6489101 USD
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6168501 USD
CY2018Q2 arth Common Stock Subscription Received Un Issued
CommonStockSubscriptionReceivedUnIssued
2137546 USD
CY2017Q3 arth Common Stock Subscription Received Un Issued
CommonStockSubscriptionReceivedUnIssued
0 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y8M19D
arth Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedWeightedAverageRemainingContractualTerm
P0Y
arth Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm
P0Y
arth Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm
P0Y
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
2397454 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
2996110 USD
arth Financing Costs On Issuance Of Common Stock And Warrants
FinancingCostsOnIssuanceOfCommonStockAndWarrants
80000 USD
arth Financing Costs On Issuance Of Common Stock And Warrants
FinancingCostsOnIssuanceOfCommonStockAndWarrants
0 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P4Y1M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y5M16D
us-gaap Stock Issued1
StockIssued1
117 USD
us-gaap Stock Issued1
StockIssued1
107 USD
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6178263 USD
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
225000 shares
CY2013Q2 arth Increase In Aggregate Number Of Shares
IncreaseInAggregateNumberOfShares
3000000 shares
arth Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedAggregateIntrinsicValue
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
arth Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodAggregateIntrinsicValue
0 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1788273 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9315 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.1944 pure
CY2018Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1716680 USD
CY2014Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
224000 USD
CY2015Q1 arth Gain Loss On Warrant Derivative Modification
GainLossOnWarrantDerivativeModification
624016 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
1788273 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0131 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0285 pure
arth Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4467314 shares
CY2015Q2 us-gaap Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity
EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity
3263753 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
628000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1058000 USD
CY2018Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
505000 USD
CY2016Q3 us-gaap Share Price
SharePrice
0.72
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
225000 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
375000 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
1750000 shares
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
1 pure
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Interest Paid Net
InterestPaidNet
361268 USD
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
32844870 USD
CY2017Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
31580022 USD
CY2018Q2 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
9070000 shares
CY2017Q3 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
0 shares
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4598388 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5524781 USD
CY2018Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
2397454 USD
arth Stock Issued During Period Value Restricted Stock Vested
StockIssuedDuringPeriodValueRestrictedStockVested
233 USD
arth Stock Issued During Period Value Restricted Stock Vested
StockIssuedDuringPeriodValueRestrictedStockVested
0 USD
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32882271 USD
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29503446 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
2250680 USD
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
2226519 USD
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6599447 USD
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6090083 USD

Files In Submission

Name View Source Status
0001144204-18-041594-index-headers.html Edgar Link pending
0001144204-18-041594-index.html Edgar Link pending
0001144204-18-041594.txt Edgar Link pending
0001144204-18-041594-xbrl.zip Edgar Link pending
arth-20180630.xml Edgar Link completed
arth-20180630.xsd Edgar Link pending
arth-20180630_cal.xml Edgar Link unprocessable
arth-20180630_def.xml Edgar Link unprocessable
arth-20180630_lab.xml Edgar Link unprocessable
arth-20180630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv498952_10q.htm Edgar Link pending
tv498952_ex31-1.htm Edgar Link pending
tv498952_ex31-2.htm Edgar Link pending
tv498952_ex32-1.htm Edgar Link pending